Tower Research Capital LLC TRC Lowers Stock Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Tower Research Capital LLC TRC trimmed its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 74.7% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,547 shares of the specialty pharmaceutical company's stock after selling 4,565 shares during the quarter. Tower Research Capital LLC TRC's holdings in ANI Pharmaceuticals were worth $86,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Exchange Traded Concepts LLC boosted its stake in shares of ANI Pharmaceuticals by 2.6% in the 4th quarter. Exchange Traded Concepts LLC now owns 12,366 shares of the specialty pharmaceutical company's stock valued at $684,000 after purchasing an additional 310 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its position in shares of ANI Pharmaceuticals by 10.2% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 4,457 shares of the specialty pharmaceutical company's stock valued at $246,000 after purchasing an additional 412 shares in the last quarter. Natixis Advisors LLC grew its stake in ANI Pharmaceuticals by 2.3% in the fourth quarter. Natixis Advisors LLC now owns 18,601 shares of the specialty pharmaceutical company's stock worth $1,028,000 after purchasing an additional 417 shares during the period. US Bancorp DE lifted its position in ANI Pharmaceuticals by 842.9% during the fourth quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company's stock valued at $33,000 after buying an additional 531 shares during the period. Finally, KBC Group NV lifted its position in ANI Pharmaceuticals by 89.2% during the fourth quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company's stock valued at $70,000 after buying an additional 600 shares during the period. 76.05% of the stock is currently owned by institutional investors.

ANI Pharmaceuticals Stock Up 1.3%

ANIP stock traded up $0.76 on Thursday, hitting $61.13. 76,426 shares of the company's stock were exchanged, compared to its average volume of 294,789. The firm has a 50 day moving average price of $66.92 and a two-hundred day moving average price of $60.73. ANI Pharmaceuticals, Inc. has a 12-month low of $52.50 and a 12-month high of $77.00. The stock has a market cap of $1.33 billion, a P/E ratio of -109.84 and a beta of 0.56. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last announced its quarterly earnings data on Friday, May 9th. The specialty pharmaceutical company reported $1.70 earnings per share for the quarter, beating analysts' consensus estimates of $1.37 by $0.33. The business had revenue of $197.12 million for the quarter, compared to analyst estimates of $179.75 million. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The company's revenue was up 43.4% on a year-over-year basis. During the same period in the prior year, the company earned $0.82 earnings per share. As a group, equities research analysts expect that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the company. Truist Financial raised their price objective on ANI Pharmaceuticals from $62.00 to $65.00 and gave the company a "hold" rating in a research report on Monday, April 21st. JPMorgan Chase & Co. assumed coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, March 12th. They set an "overweight" rating and a $85.00 price target for the company. Jefferies Financial Group assumed coverage on ANI Pharmaceuticals in a research report on Friday, March 14th. They issued a "buy" rating and a $80.00 price objective on the stock. Guggenheim restated a "buy" rating and issued a $86.00 price target on shares of ANI Pharmaceuticals in a research note on Monday. Finally, HC Wainwright reaffirmed a "buy" rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a research report on Monday, March 17th. One analyst has rated the stock with a sell rating, one has issued a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, ANI Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average price target of $80.13.

Insider Activity

In other news, SVP Krista Davis sold 1,000 shares of the firm's stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $60.86, for a total value of $60,860.00. Following the transaction, the senior vice president now directly owns 66,525 shares of the company's stock, valued at approximately $4,048,711.50. This trade represents a 1.48% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, VP Meredith Cook sold 400 shares of the business's stock in a transaction that occurred on Monday, April 14th. The stock was sold at an average price of $68.96, for a total value of $27,584.00. Following the transaction, the vice president now owns 80,145 shares in the company, valued at approximately $5,526,799.20. This represents a 0.50% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 2,800 shares of company stock worth $173,976 in the last ninety days. Company insiders own 11.10% of the company's stock.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.